Related Experiment Video
Updated: Jun 9, 2026
13:35
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
Bilateral Nonsynchronous Male Breast Cancer: Two Case Reports
Yoshiya Horimoto1, Mako Hino, Mitsue Saito
1Department of Breast Surgical Oncology, Juntendo University School of Medicine, Tokyo, Japan.
Breast Care (Basel, Switzerland)
|September 9, 2010
Summary
Bilateral male breast cancer (MBC) is rare. Endocrine therapy, particularly aromatase inhibitors, may be less effective in men due to higher androgen levels, necessitating tailored treatment approaches.
Area of Science:
- Oncology
- Endocrinology
- Male Health
Background:
- Bilateral male breast cancer (MBC) is an uncommon diagnosis.
- Endocrine therapy is a cornerstone in managing hormone receptor-positive MBC.
- The efficacy of endocrine agents in men differs from that in women.
Observation:
- Two cases of bilateral, nonsynchronous MBC are presented.
- Second primary MBCs developed during selective estrogen receptor modulator (SERM) therapy.
- Both patients had hormone receptor-positive second cancers, continuing SERM treatment.
Findings:
- Aromatase inhibitors (AIs) show reduced efficacy in men compared to women.
- Higher endogenous androgen levels in men are hypothesized to impact AI effectiveness.
- The distinct hormonal milieu in men requires specific therapeutic considerations.
Implications:
- Current treatments for early-stage MBC remain under investigation.
- Novel therapeutic strategies are needed to optimize MBC management in men.
- Further research is crucial to enhance aromatase inhibitor efficacy for male breast cancer.
